Enlivex Therapeutics (NASDAQ:ENLV) Given New $20.00 Price Target at HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV) had its price target lifted by HC Wainwright from $13.00 to $20.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. Wall Street Zen lowered shares of Enlivex Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $16.50.

Enlivex Therapeutics Trading Down 4.6%

Shares of NASDAQ ENLV opened at $0.83 on Tuesday. The firm has a 50 day moving average of $1.08 and a 200 day moving average of $1.02. The firm has a market capitalization of $197.83 million, a price-to-earnings ratio of -1.52 and a beta of 1.68. Enlivex Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.10.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds have recently modified their holdings of ENLV. Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Citizens Financial Group Inc. RI bought a new position in shares of Enlivex Therapeutics in the third quarter worth approximately $241,000. Susquehanna International Group LLP bought a new position in shares of Enlivex Therapeutics in the third quarter worth approximately $57,000. Renaissance Technologies LLC boosted its position in shares of Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after purchasing an additional 156,336 shares during the period. Finally, HRT Financial LP boosted its position in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the period. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.